Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...
ph.investing.com on MSN25d
Wall Street analysts initiate coverage of BioAge LabsBioAge Labs, a clinical-stage biotech company developing therapies for metabolic diseases, has attracted attention from Wall ...
RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic ...
"Our preclinical data highlight the potential of azelaprag as a novel oral therapy for obesity," said Kristen Fortney, Ph.D., CEO and co-founder of BioAge. “Our two presentations provide evidence ...
On Monday, BioAge Labs Inc (NASDAQ:BIOA) stock received a positive outlook from a major financial institution, as coverage was initiated with a Buy rating and a price target set at $42. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback